A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
← catalyst calendarNCT06830863 · readout in 149 d
Sponsored by Azitra Inc. (industry) · AZTR — their whole pipeline →. With Prosoft Clinical.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
32estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-25 | actual | When the study began enrolling |
| Primary completion | 2027-01-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- EGFR Inhibitor-associated Rash
Interventions
- Drug: ATR04-484 — also filed as ATR-04
- Drug: Vehicle
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability
measured 57 days
Permalink · AZTR's whole pipeline · Catalyst calendar · Every registered study · What changed